Total Payments
$5,463
2024 Payments
$237.19
Companies
6
Transactions
17
Payment Breakdown by Category
Research$5,206 (95.3%)
Food & Beverage$256.50 (4.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5,206 | 12 | 95.3% |
| Food and Beverage | $256.50 | 5 | 4.7% |
Payments by Type
Research
$5,206
12 transactions
General
$256.50
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Chiasma, Inc. | $4,441 | 11 | $0 (2021) |
| Amryt Pharma Holdings Ltd | $765.00 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $109.85 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $91.54 | 1 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $39.45 | 2 | $0 (2024) |
| ANI Pharmaceuticals, Inc. | $15.66 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $237.19 | 4 | AstraZeneca Pharmaceuticals LP ($109.85) |
| 2023 | $19.31 | 1 | Bayer Healthcare Pharmaceuticals Inc. ($19.31) |
| 2021 | $5,206 | 12 | Chiasma, Inc. ($4,441) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/17/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: Cardio-pulmonary | ||||||
| 08/15/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $91.54 | General |
| Category: RESPIRATORY | ||||||
| 04/29/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $109.85 | General |
| Category: Respiratory | ||||||
| 12/19/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: Cardio-pulmonary | ||||||
| 11/30/2021 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | — | Cash or cash equivalent | $765.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THREE ESCALATING DOSES OF MYCAPSSA • Category: Endocrinology | ||||||
| 07/15/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $680.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 07/15/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $680.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 07/15/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $212.50 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 06/15/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $85.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 05/31/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $616.25 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 05/31/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $552.50 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 05/31/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $467.50 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 05/15/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $467.50 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 05/15/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $255.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 04/30/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $255.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
| 04/30/2021 | Chiasma, Inc. | MYCAPSSA (Drug) | — | Cash or cash equivalent | $170.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA • Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA | Chiasma, Inc. | $4,441 | 11 |
| A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THREE ESCALATING DOSES OF MYCAPSSA | Amryt Pharma Holdings Ltd | $765.00 | 1 |
About Timothy Kell, NP
Timothy Kell, NP is a Adult Health healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2008. The National Provider Identifier (NPI) number assigned to this provider is 1346415718.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Timothy Kell, NP has received a total of $5,463 in payments from pharmaceutical and medical device companies, with $237.19 received in 2024. These payments were reported across 17 transactions from 6 companies. The most common payment nature is "" ($5,206).
Ad
Practice Information
- Specialty Adult Health
- Location Saint Louis, MO
- Active Since 04/28/2008
- Last Updated 10/26/2023
- Taxonomy Code 363LA2200X
- Entity Type Individual
- NPI Number 1346415718
Products in Payments
- MYCAPSSA (Drug) $5,206
- TEZSPIRE (Biological) $109.85
- AREXVY (Drug) $91.54
- Adempas (Drug) $39.45
- PURIFIED CORTROPHIN GEL (Drug) $15.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Adult Health Doctors in Saint Louis
Stephanie Vogel, Np-C, NP-C
Adult Health — Payments: $48,935
Adult Health $48,935
Jennifer Speiser, Np, NP
Adult Health — Payments: $14,376
Adult Health $14,376
Michele Nobs, N.p, N.P
Adult Health — Payments: $11,208
Adult Health $11,208
Allyson Granden, Np-C, NP-C
Adult Health — Payments: $10,285
Adult Health $10,285
Marcee Stegemeier, Aprn-Bc, APRN-BC
Adult Health — Payments: $9,559
Adult Health $9,559
Heather Popham, Np, NP
Adult Health — Payments: $9,056
Adult Health $9,056